Skip to main content

A case of JAK2 V617F positive essential thrombocythemia successfully controlled by imatinib mesylate

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. Tefferi A, Pardanani A (2019) Essential thrombocythemia. N Engl J Med 381:2135–2144

    Article  Google Scholar 

  2. Wan Z, Han B (2020) Comparison and implications of mutational profiles of myelodysplastic syndromes, myeloproliferative neoplasms, and myelodysplastic/myeloproliferative neoplasms: a meta-analysis. Front Oncol 10:579221

    Article  Google Scholar 

  3. Nussenzveig RH, Cortes J, Sever M et al (2009) Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. Int J Hematol 90:58–63

    CAS  Article  Google Scholar 

  4. Mesa RA (2007) Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders. Biologics 1:129–138

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Cortes J, Kantarjian H (2004) Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders. Cancer 100:2064–2078

    CAS  Article  Google Scholar 

  6. Green MR, Newton MD, Fancher KM (2016) Off-target effects of BCR-ABL and JAK2 inhibitors. Am J Clin Oncol 39:76–84

    CAS  Article  Google Scholar 

  7. Zhou LX, Liang EY, Ye JY, Yang M (2016) Role of PDGF/PDGFR pathway in essential thrombocythemia and its action mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi 24:526–530

    CAS  PubMed  Google Scholar 

  8. Tefferi A, Vannucchi AM, Barbui T (2018) Essential thrombocythemia treatment algorithm 2018. Blood Cancer J 8:2

    Article  Google Scholar 

  9. Cortelazzo S, Finazzi G, Ruggeri M et al (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332:1132–1136

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mineo Kurokawa.

Ethics declarations

Full informed consent was obtained from the patient in this report for the treatment. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Written informed consent to publish was obtained from the patient.

Conflit of interest

Dr. YM received lecture fees from Bristol Myers Squibb and Takeda Pharmaceutical Co.Ltd. Dr. MK received lecture fees from Bristol Myers Squibb and lecture fees and scholarship donations from Takeda Pharmaceutical Co., Ltd. The other authors (Drs. KE, KY) declared that they had no relevant financial relationships to disclose.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ebisawa, K., Masamoto, Y., Yagi, K. et al. A case of JAK2 V617F positive essential thrombocythemia successfully controlled by imatinib mesylate. Ann Hematol (2022). https://doi.org/10.1007/s00277-022-04940-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00277-022-04940-6